What does MOTS-C do?
MOTS-C is studied for its potential role in supporting insulin sensitivity, fat metabolism, and mitochondrial energy signaling, sometimes described as an exercise mimetic.
Is MOTS-C FDA-approved?
No. MOTS-C does not have FDA approval for any use, and its regulatory status for pharmacy compounding has changed over time and continues to be actively reviewed.
How long before I may notice changes?
Responses vary considerably, and because human clinical trial data is very limited, there is no well-established timeline for expected results.
Is it an injection?
Yes, MOTS-C is typically administered as a subcutaneous injection.
Can it be combined with other peptides?
This should be discussed with your provider, who can evaluate your full treatment plan and goals.
Can it be combined with GLP-1 medications?
This should be discussed individually and carefully with your provider, particularly given MOTS-C’s studied effects on blood sugar regulation.
Will I need lab work?
Your provider may recommend baseline metabolic and glucose-related lab testing as part of a thorough, individualized approach to this peptide.
Who should avoid this peptide?
Patients with diabetes or other blood sugar-related conditions require particularly close monitoring. A full medical evaluation will help determine appropriateness.
How long do patients typically remain on therapy?
Treatment length varies by individual goals, and given the evolving evidence base, your provider will help determine a reasonable, individualized plan.
Is a consultation required?
Yes. A telehealth consultation with a licensed medical provider is required before starting MOTS-C or any peptide therapy at SevenHealth.